24th Jun 2020 15:21
Oxford BioMedica PLC - Oxford, England-based cell therapy firm - Non-Executive Director Martin Diggle sells 223,583 shares via Vulpes Testudo Fund and Vulpes Life Sciences Fund at 807.8 pence, worth GBP1.8 million, on Monday. The two funds now hold 11.5 million shares, a 14% stake. The investment in Oxford BioMedica had become an increasingly significant portion of the funds under management for the two life sciences funds, the company explained, and the sale proceeds are expected to be invested in other portfolio companies in the near future.
Current stock price: 762.00p
Year-to-date change: up 13%
By Tom Waite; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica